Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1986 Dec;59(4):589–594.

Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice.

A Tarkowski, K Gunnarsson, T Stålhandske
PMCID: PMC1453312  PMID: 3804379

Abstract

Autoimmune (NZB X NZW) F1 female hybrid mice were treated with LS-2616, a recently developed substance with immunomodulating properties. Treatment was initiated at the age of 4 months (i.e. at the early stage of the disease) as well as at 7 months of age (i.e. after the development of established lupus-like disease). Control groups treated with cyclophosphamide and physiological saline were also studied. Beneficial therapeutic effects were obtained regardless of when the treatment was initiated and the dose of LS-2616 administered (1 and 8 mg/mouse/week). The effects of LS-2616 on longevity, splenomegaly and glomerulonephritis were pronounced and sometimes comparable to those of cyclophosphamide (1.8 mg/mouse/week). The results obtained suggest that LS-2616 may be useful in the treatment of autoimmune disease in man.

Full text

PDF
589

Images in this article

591Figure 3
on p.591

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarden L. A., de Groot E. R., Feltkamp T. E. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci. 1975 Jun 30;254:505–515. doi: 10.1111/j.1749-6632.1975.tb29197.x. [DOI] [PubMed] [Google Scholar]
  2. Alcocer-Varela J., Alarcón-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest. 1982 Jun;69(6):1388–1392. doi: 10.1172/JCI110579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dauphinée M. J., Kipper S. B., Wofsy D., Talal N. Interleukin 2 deficiency is a common feature of autoimmune mice. J Immunol. 1981 Dec;127(6):2483–2487. [PubMed] [Google Scholar]
  4. Gelfand M. C., Steinberg A. D. Therapeutic studies in NZB-W mice. II. Relative efficacy of azathioprine, cyclophosphamide and methylprednisolone. Arthritis Rheum. 1972 May-Jun;15(3):247–252. doi: 10.1002/art.1780150305. [DOI] [PubMed] [Google Scholar]
  5. Horwitz D. A. Impaired delayed hypersensitivity in systemic lupus erythematosus. Arthritis Rheum. 1972 Jul-Aug;15(4):353–359. doi: 10.1002/art.1780150406. [DOI] [PubMed] [Google Scholar]
  6. Howie J. B., Helyer B. J. The immunology and pathology of NZB mice. Adv Immunol. 1968;9:215–266. doi: 10.1016/s0065-2776(08)60444-7. [DOI] [PubMed] [Google Scholar]
  7. Hurd E. R., Ziff M. The mechanism of action of cyclophosphamide on the nephritis of (NZB x NZW)F1 hybrid mice. Clin Exp Immunol. 1977 Jul;29(1):132–139. [PMC free article] [PubMed] [Google Scholar]
  8. Jones M. G., Harris G. Prolongation of life in female NZB/NZW (F1) hybrid mice by cyclosporin A. Clin Exp Immunol. 1985 Jan;59(1):1–9. [PMC free article] [PubMed] [Google Scholar]
  9. Kalland T., Alm G., Stålhandshe T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol. 1985 Jun;134(6):3956–3961. [PubMed] [Google Scholar]
  10. Kelley V. E., Ferretti A., Izui S., Strom T. B. A fish oil diet rich in eicosapentaenoic acid reduces cyclooxygenase metabolites, and suppresses lupus in MRL-lpr mice. J Immunol. 1985 Mar;134(3):1914–1919. [PubMed] [Google Scholar]
  11. Kelley V. E., Winkelstein A., Izui S., Dixon F. J. Prostaglandin E1 inhibits T-cell proliferation and renal disease in MRL/1 mice. Clin Immunol Immunopathol. 1981 Nov;21(2):190–203. doi: 10.1016/0090-1229(81)90208-7. [DOI] [PubMed] [Google Scholar]
  12. Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
  13. Neighbour P. A., Grayzel A. I., Miller A. E. Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis. Clin Exp Immunol. 1982 Jul;49(1):11–21. [PMC free article] [PubMed] [Google Scholar]
  14. Pereira A. B., Theofilopoulos A. N., Dixon F. J. Detection and partial characterization of circulating immune complexes with solid-phase anti-C3. J Immunol. 1980 Aug;125(2):763–770. [PubMed] [Google Scholar]
  15. Prickett J. D., Robinson D. R., Steinberg A. D. Effects of dietary enrichment with eicosapentaenoic acid upon autoimmune nephritis in female NZB X NZW/F1 mice. Arthritis Rheum. 1983 Feb;26(2):133–139. doi: 10.1002/art.1780260203. [DOI] [PubMed] [Google Scholar]
  16. Russell P. J., Hicks J. D. Cyclophosphamide treatment of renal disease in (NZB x NZW) F1 hybrid mice. Lancet. 1968 Mar 2;1(7540):440–441. doi: 10.1016/s0140-6736(68)92778-5. [DOI] [PubMed] [Google Scholar]
  17. Scott C. F., Jr, Tsurufuji M., Lu C. Y., Finberg R., Sy M. S. Comparison of antigen-specific T cell responses in autoimmune MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice. J Immunol. 1984 Feb;132(2):633–639. [PubMed] [Google Scholar]
  18. Shear H. L., Wofsy D., Talal N. Effects of castration and sex hormones on immune clearance and autoimmune disease in MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice. Clin Immunol Immunopathol. 1983 Mar;26(3):361–369. doi: 10.1016/0090-1229(83)90120-4. [DOI] [PubMed] [Google Scholar]
  19. Tarkowski A., Czerkinsky C., Nilsson L. A. Detection of IgG rheumatoid factor secreting cells in autoimmune MRL/1 mice: a kinetic study. Clin Exp Immunol. 1984 Oct;58(1):7–12. [PMC free article] [PubMed] [Google Scholar]
  20. Theofilopoulos A. N., Dixon F. J. Etiopathogenesis of murine SLE. Immunol Rev. 1981;55:179–216. doi: 10.1111/j.1600-065x.1981.tb00343.x. [DOI] [PubMed] [Google Scholar]
  21. Toivonen M. L., Lindén I. B., Gripenberg M., Vapaatalo H. The usability of the MRL/1 mouse strain in detection of anti-rheumatic drugs. Agents Actions. 1984 Dec;15(5-6):578–583. doi: 10.1007/BF01966777. [DOI] [PubMed] [Google Scholar]
  22. Walker S. E., Solsky M., Schnitzer B. Prolonged lifespans in female NZB/NZW mice treated with the experimental immunoregulatory drug frentizole. Arthritis Rheum. 1982 Nov;25(11):1291–1297. doi: 10.1002/art.1780251104. [DOI] [PubMed] [Google Scholar]
  23. Zulman J., Michalski J., McCombs C., Greenspan J., Talal N. Levamisole maintains cyclophsophamide-induced remission in murine lupus erythematosus. Clin Exp Immunol. 1978 Feb;31(2):321–327. [PMC free article] [PubMed] [Google Scholar]
  24. Zurier R. B., Sayadoff D. M., Torrey A. B., Rothfield N. F. Prostaglandin E treatment of NZB/NZW mice. Arthritis Rheum. 1977 Mar;20(2):723–728. doi: 10.1002/art.1780200213. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES